Our Managing Partner Ioanna Michalopoulou joined on 16th June 2023 the Greek Biopharma Innovation panel – organized by 3rd Hellenic Biocluster (HBio) Forum 2023, where key biotech scientists and business leaders discussed the impact of the long awaited EU Pharma Reform.
In her keynote, she talked about the critical importance of the 3𝐀𝐬 of the upcoming EU pharma reform: Access, Availability, Affordability.
Personalized medicine features as a key concept in the upcoming pharma reform and is deeply critical for patients.
However, the 1st 𝐀 (‘𝐀𝐜𝐜𝐞𝐬𝐬’) including pricing, reimbursement and procurement is in fact left at national competence, meaning that individual countries might pose limitations in patients’ access.
Legal solidarity amongst member states is paramount in order to achieve biotech innovation; uniform criteria will procure uniform access, thus steady supply of pharma products to patients in Greece and across all Europe.
Concluding, she pointed out that developments in the legislation are bound to have implications for startups, for mature business seeking growth, as well as for clinical trials providers. Nevertheless, change is the only constant, and adapting to it swiftly is key to bringing about progress and innovation in the booming Greek biotech industry.
